Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.

Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.
复制标题

DOI:
10.1007/s10552-010-9557-y
复制
发表时间:
2010-08
期刊:
Cancer causes & control : CCC
影响因子:
--
通讯作者:
Beer TM
Beer TM
中科院分区:
其他
文献类型:
--
作者:
Barnett CM;Nielson CM;Shannon J;Chan JM;Shikany JM;Bauer DC;Hoffman AR;Barrett-Connor E;Orwoll E;Beer TM

文献摘要

参考文献

被引文献

相似文献

多项研究在实验室实验中显示了维生素D对前列腺癌细胞的抗肿瘤作用的明确证据,但在人类中的证据并不一致。我们试图在一组老年男性中研究维生素D与前列腺癌风险之间的关系。我们在多中心男性骨质疏松性骨折(MrOS)研究中进行了一项前瞻性病例队列研究。基线血清25-OH维生素D是在一个随机选择的子队列中测量的,该子队列包括1,433名年龄≥65岁、无前列腺癌病史的男性和所有诊断为前列腺癌的参与者(n = 297)。考克斯比例风险模型用于评估总25-羟基维生素D的四分位数与前列腺癌发病率以及Gleason评分之间的相关性。与25-OH维生素D的最低四分位数相比,25-OH维生素D的最高四分位数的风险比为1.22(CI 0.50-1.72,p = 0.25),未观察到跨四分位数的趋势(p = 0.94)或与Gleason评分的相关性。协变量调整未改变结果。在这个老年男性的前瞻性队列中,我们发现血清25-OH维生素D水平与随后的前列腺癌风险之间没有关联。
Multiple studies have shown clear evidence of vitamin D’s anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men. We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men ≥65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score. In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50–1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results. In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.
DOI: 10.1016/s0090-4295(97)00408-1
发表时间: 1997-12-01
期刊: UROLOGY
影响因子: 2.1
作者:
Getzenberg, RH;Light, BW;Johnson, CS
通讯作者: Johnson, CS
DOI: 10.1016/j.cct.2005.05.006
发表时间: 2005-10-01
影响因子: 2.2
作者:
Orwoll, E;Blank, JB;Stone, K
通讯作者: Stone, K
DOI: 10.1093/jnci/djn152
发表时间: 2008-06-04
影响因子: 10.3
作者:
Ahn, Jiyoung;Peters, Ulrike;Hayes, Richard B.
通讯作者: Hayes, Richard B.
DOI: 10.1158/0008-5472.can-04-3134
发表时间: 2005-06-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
John, EM;Schwartz, GG;Ingles, SA
通讯作者: Ingles, SA
DOI: 10.1016/s0140-6736(01)05788-9
发表时间: 2001-08-25
期刊: LANCET
影响因子: 168.9
作者:
Luscombe, CJ;Fryer, AA;Strange, RC
通讯作者: Strange, RC